Vogt‐Koyanagi‐Harada disease‐like uveitis after drug therapy including BRAF/MEK inhibitors in melanoma patients with HLA‐DRB1*04

Abstract

AbstractThe combination of BRAF kinase inhibitors (BRAFis) and MEK kinase inhibitors (MEKis) is one of the most promising chemotherapy regimens in the treatment of BRAF‐mutant melanoma. Although BRAFi plus MEKi combined therapy is widely used for the treatment of BRAFV600‐mutated melanoma, the incidence of uveitis caused by BRAFi plus MEKi is limited. In this report, we described five cases (two men and three women) of Vogt‐Koyanagi‐Harada (VKH) disease‐like uveitis in melanoma patients who received BRAFi plus MEKi combined therapy. Of note, all the patients had the HLA‐DRB1*04 haplotype, which is frequently detected in VKH‐like non‐infectious uveitis. On the other hand, among BRAFi plus MEKi‐treated patients who did not develop VKH disease‐like uveitis, only one of five (20%) patients had the HLA‐DRB1*04 haplotype. Collectively, BRAFi/MEKi might induce severe VKH disease‐like uveitis in melanoma patients with the HLA‐DRB1*04 haplotype.